**Core tip:** Although for cap polyposis, conservative treatment should be selected as first-line therapy, the optimal treatment of cap polyposis refractory to conservative treatment has not been established. Endoscopic submucosal dissection may be a treatment option for cases refractory to conservative treatment.

INTRODUCTION
============

Cap polyposis is a rare intestinal disorder with unique clinical, endoscopic, and histological findings. Clinical symptoms include mucoid and bloody diarrhea, abdominal pain, tenesmus, weight loss, and dysplasia. Endoscopy typically reveals multiple reddish, mucus-capped inflammatory polyps in the rectosigmoid area with normal mucosa interspersed between the polyps\[[@B1]\]. Pathologically, the surfaces of these inflammatory polyps are covered by a thick layer of fibrinopurulent exudate, hence the term "cap"\[[@B1]\]. However, the etiology of cap polyposis is unclear and its clinical course varies from spontaneous clinical and endoscopic remission without treatment\[[@B2]-[@B4]\] to persistent disease refractory to conservative treatment\[[@B5]-[@B7]\], requiring surgical resection. Little is known about its long-term course.

The optimal treatment for cap polyposis has not been established\[[@B2]-[@B16]\]. Some cases have been treated successfully by the avoidance of straining at defecation\[[@B8]\], antimicrobial agents (*i.e*., metronidazole)\[[@B9]\], steroids\[[@B2]\], immunomodulators (*i.e*., infliximab)\[[@B12]\], endoscopic therapy\[[@B13],[@B14]\] and surgical resection\[[@B5]-[@B7]\]. Recently, the efficacy of *Helicobacter pylori* (*H. pylori*) eradication therapy for *H. pylori-*positive patients with cap polyposis has been reported\[[@B10],[@B11],[@B15],[@B16]\], and in 2016 the Japanese Society for *Helicobacter* Research added cap polyposis as a possible *H. pylori*-associated disease in its treatment guidelines. However, no treatments for *H. pylori*-negative cap polyposis or *H. pylori*-positive cases refractory to eradication therapy have yet been established.

Here, we report a case of *H. pylori*-negative cap polyposis refractory to *H. pylori* eradication therapy that was successfully treated with endoscopic submucosal dissection (ESD). We also review the literature concerning conservative and endoscopic treatments for cap polyposis.

CASE REPORT
===========

A 20-year-old Japanese man presented with a 1-year history of hematochezia and tenesmus. He denied straining at stool and had no history of anal prolapse. His past medical and family history were unremarkable. Laboratory tests revealed mild hypoproteinemia (serum albumin 3.9 g/L), but no hepatic or renal dysfunction, leukocytosis, elevation of C-reactive protein, or anemia. Colonoscopy revealed the characteristic appearance of cap polyposis, with approximately 20-30 erythematous variform inflammatory polyps with white caps of fibrinopurulent exudate from the sigmoid colon to the rectum (Figure [1A](#F1){ref-type="fig"} and B). Magnification endoscopy with narrow-band imaging showed amorphous exudate in the white caps overlying long branching tortuous crypts in the basal part of the polyps (Figure [1C](#F1){ref-type="fig"} and D). Endoscopic ultrasonography (EUS) with radial array scanning showed significant thickening of the mucosa without evidence of invasion into the submucosa (Figure [1E](#F1){ref-type="fig"}). Histologic findings from a polyp revealed elongated, tortuous, branched crypts lined with hyperplastic epithelium with inflammatory cell infiltration and a mild degree of fibromusculosis in the lamina propria (Figure [2](#F2){ref-type="fig"}). The surface of the polyps was covered by thick inflammatory granulation tissue with exudate (Figure [2](#F2){ref-type="fig"}). The intervening mucosa between lesions was histologically normal. Computed tomography and magnetic resonance imaging showed multiple elevated lesions thickening the walls of the sigmoid colon and rectum (Figure [3A](#F3){ref-type="fig"} and B). Barium enema showed multiple raised mucosal lesions without stenosis or sclerotic changes in the sigmoid colon and rectum (Figure [3C](#F3){ref-type="fig"}). The differential diagnosis included the mucosal prolapse syndrome, inflammatory polyps, colon cancer, malignant lymphoma, inflammatory bowel disease, and adenomatous polyposis. We diagnosed cap polyposis based on the endoscopic and histopathological characteristics.

![Endoscopic findings of multiple inflammatory polyps. A and B: Caps of fibrinopurulent exudate from the sigmoid colon to the rectum interspersed with normal colonic mucosa; C and D: Magnifying endoscopy shows an area in the cap of amorphous fibrinopurulent exudate and tortuous and long branching crypts under the cap; E: Endoscopic ultrasonography showed significant thickening of the colonic mucosa layers.](WJGE-9-529-g001){#F1}

![Microscopic findings of inflammatory polyps show elongated, tortuous, branched, and dilated crypts with epithelial hyperplasia, inflammatory granulation tissue and a mild degree of fibromusculosis in the lamina propria. Hematoxylin-Eosin stain, × 4 (A) and × 20 (B).](WJGE-9-529-g002){#F2}

![Multiple elevated lesions with wall thickening in the sigmoid colon. Rectum on computed tomography (A) and magnetic resonance imaging (B); Barium enema shows a collection of small sessile polyps in the sigmoid colon and rectum (C).](WJGE-9-529-g003){#F3}

The patient had no evidence of *H. pylori* infection by urea breath test, anti-*H. pylori* antibody, or endoscopic findings (*i.e*., gastric mucosal atrophy or diffuse redness of gastric mucosa). However, according to previous evidence that *H. pylori* eradication therapy was effective for patients with cap polyposis\[[@B10],[@B11],[@B15],[@B16]\], *H. pylori* eradication therapy with vonoprazan 20 mg, amoxicillin 750 mg and clarithromycin 200 mg twice daily for 7 d was initiated. Abdominal symptoms (*i.e*., hematochezia and tenesmus), bowel habits, and endoscopic findings did not improve over the six months after therapy. Therefore, as conservative alternative treatment, we performed *en bloc* excision of the polyps with ESD (Figure [4](#F4){ref-type="fig"}). After resection, the patient's symptoms disappeared and he had no endoscopic evidence of recurrence for six months.

![Endoscopic submucosal dissection. Post-dissection ulcers after endoscopic submucosal dissection at the sigmoid colon and rectum (A). Fresh specimen of cap polyposis after endoscopic submucosal dissection (B) and fixed specimen (C). The fixed specimen revealed bleeding into the polyps. Microscopic findings of inflammatory polyps \[HE stain, × 4 (D)\].](WJGE-9-529-g004){#F4}

DISCUSSION
==========

We report a case of a patient with cap polyposis refractory to *H. pylori* eradication therapy who then underwent *en bloc* excision of polyps by ESD with good results. This is the first report of the efficacy of ESD for treatment of cap polyposis. More studies of ESD as a treatment option for cap polyposis are needed to validate its use instead of surgical resection.

Diagnosis of cap polyposis
--------------------------

Cap polyposis can be difficult to diagnose. It can resemble mucosal prolapse syndrome (MPS). There has been a debate about whether cap polyposis is a specific form of inflammatory disorder or part of a spectrum of MPS\[[@B12]\]. MPS and cap polyposis share some clinical, endoscopic, and histological features. Both diseases show infiltration of inflammatory cells with elongated stroma and fibromuscular obliteration of the lamina propria. However, the fibromuscular obliteration is more marked in cap polyposis. MPS is usually confined to the rectum, but cap polyposis usually involves the sigmoid and/or descending colon as well as the rectum. EUS findings in cap polyposis show significant thickening of the mucosa\[[@B9]\], whereas MPS is characterized by smooth, diffuse thickening of the submucosa and minimal thickening of the lamina propria\[[@B17]\].

Cap polyposis and protein loss
------------------------------

Common clinical features of cap polyposis are hematochezia (82%), chronic straining (64%), and mucous diarrhea (46%)\[[@B1]\]. When mucous diarrhea is severe and/or continuous for long periods, excessive protein loss is observed as a result\[[@B1],[@B5]\]. Direct loss of protein was demonstrated in a case of cap polyposis by scintigraphy with technetium 99m-labeled diethylenetriaminepentaacetic acid complexed to human serum albumin\[[@B18]\]. In our case, blood tests revealed mild hypoproteinemia, with an albumin level 39 g/L, possibly secondary to protein loss from mucous diarrhea.

Cap polyposis and H. pylori infection
-------------------------------------

Cap polyposis has been attributed to colonic dysmotility, immune abnormalities, bacterial infection (*i.e., H. pylori*) or other unknown pathogens. Géhénot et al\[[@B19]\] suggested the possibility of bacterial infection, reporting on a cap polyposis patient who had no evidence of colonic dysmotility and who was successfully treated with metronidazole. Of the myriad gut microbiota, although *H. pylori* is not detected in mucosa obtained from cap polyposis lesions\[[@B10]\], most cases of cap polyposis with *H. pylori* infection have resolved after *H. pylori* eradication therapy\[[@B10],[@B11],[@B15],[@B16],[@B18]\]. *H. pylori* infection is well-known to cause not only gastroduodenal diseases, but also diseases such as idiopathic thrombocytopenic purpura and chronic idiopathic urticaria\[[@B20],[@B21]\]. In addition, eradication therapy often induces regression of mucosa-associated lymphoid tissue (MALT) lymphoma in the rectum and thyroid\[[@B22]\]. Although an *H. pylori-*associated immune reaction may play a role in the development of some cases of cap polyposis, there is no evidence for efficacy of *H. pylori* eradication therapy in *H. pylori*-negative cap polyposis patients, as in our case. Because the development of cap polyposis with active inflammation in the colonic mucosa may be related to other bacterial infections that are also sensitive to the antimicrobial agents used in *H. pylori* eradication therapy (*i.e*., clarithromycin, amoxicillin, and metronidazole), we selected eradication therapy as the first-line treatment. Although eradication failed to cure the cap polyposis, further studies will be required to investigate whether other pathogens are related to this diagnosis, and whether their eradication can effect resolution.

Cap polyposis and endoscopic treatment
--------------------------------------

The efficacy of endoscopic treatment, such as polypectomy and endoscopic mucosal resection (EMR), for cap polyposis has been reported\[[@B12],[@B14]\]. However, *en bloc* excision is difficult to perform with conventional EMR, and the use of surgical resection is more frequent\[[@B5]-[@B7]\]. Although there have been no reports of malignant transformation, surgical resection may be excessive for the treatment of cap polyposis. We consider ESD *en bloc* excision to be less invasive, and also can prevent recurrence.

ESD, an endoscopic procedure that originated in Japan and Korea in the late 1990s which has since spread rapidly to other nations, is now commonly used to treat gastrointestinal tumors\[[@B23],[@B24]\]. ESD allows complete pathological assessment, proving this technique superior to polypectomy or conventional EMR to prevent recurrence\[[@B25]\]. To date, no case of cap polyposis treated with ESD has been reported. Our present case suggests that ESD may be an effective treatment for intractable cap polyposis, with lower invasiveness than surgical resection. Our patient remains under surveillance for recurrence.

Conclusion
----------

For cap polyposis, conservative treatment should be selected as first-line therapy. In particular, we recommend eradication therapy for *H. pylori* infection. To our knowledge, however, the optimal treatment of cap polyposis refractory to conservative medical treatment has not been established. This is the first report of cap polyposis refractory to conservative medical treatment effectively treated with ESD. We believe that ESD is less invasive and more effective than surgical resection in cases refractory to conservative treatment. ESD may be a treatment option for cap polyposis cases refractory to conservative medical treatments, such as *H pylori* eradication, metronidazole, steroids, and infliximab. Further investigation is required.

COMMENTS
========

Case characteristics
--------------------

A 20-year-old Japanese man with cap polyposis located in sigmoid colon and rectum refractory to *Helicobacter pylori* (*H. pylori*) eradication and resected with endoscopic submucosal dissection.

Clinical diagnosis
------------------

Cap polyposis.

Differential diagnosis
----------------------

Although the differential diagnosis includes the mucosal prolapse syndrome (MPS), inflammatory polyps, colon cancer, malignant lymphoma, inflammatory bowel disease, and adenomatous polyposis, MPS is most possible disease as differentiation disease, because cap polyposis and MPS share some clinical, endoscopic, and histological features.

Laboratory diagnosis
--------------------

Although mild hypoproteinemia was revealed, there was no hepatic or renal dysfunction, leukocytosis, elevation of C-reactive protein, or anemia.

Imaging diagnosis
-----------------

Colonoscopy revealed the characteristic appearance of cap polyposis, with approximately 20-30 erythematous variform inflammatory polyps with white caps of fibrinopurulent exudate from the sigmoid colon to the rectum.

Pathological diagnosis
----------------------

Pathological findings revealed elongated, tortuous, branched crypts lined with hyperplastic epithelium with inflammatory cell infiltration and a mild degree of fibromusculosis in the lamina propria in the polypoid lesion and thick inflammatory granulation tissue in the surface of the polyps.

Treatment
---------

Because this case was refractory to *H. pylori* eradication as the first-line therapy, *en bloc* excision of polyposis with endoscopic submucosal dissection (ESD) was selected as second-line therapy.

Related reports
---------------

Previously, although endoscopic treatment including polypectomy and EMR, and conservative medical treatments including *H. pylori* eradication, metronidazole, steroids, and infliximab, had been reported, the optimal treatment for cap polyposis has not been established.

Experiences and lessons
-----------------------

ESD may be a treatment option for cap polyposis cases refractory to conservative treatments (*i.e., H. pylori* eradication, metronidazole, steroids, and infliximab).

Peer-review
-----------

The paper is well written.
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